The Medical Letter on Drugs and Therapeutics
Icosapent Ethyl (Vascepa) for Severe Hypertriglyceridemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Icosapent ethyl (Vascepa [vas EE puh] – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA as an adjunct to diet for treatment of severe hypertriglyceridemia (≥500 mg/dL). Vascepa is the second omega-3 polyunsaturated fatty acid (PUFA) product to become available by prescription for this indication; Lovaza (formerly Omacor), which is a combination of the ethyl esters of EPA and docosahexaenoic acid (DHA), was the first.1 Many omega-3 PUFA-containing fish oil capsules are sold over the counter as dietary supplements.2

TRIGLYCERIDE LEVELS AND RISK — Mildly (150-200 mg/dL) and moderately (200-500 mg/dL) increased levels of plasma triglycerides are associated with increased cardiovascular risk. This risk may not be due to triglycerides themselves, but rather to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Icosapent Ethyl (Vascepa) for Severe Hypertriglyceridemia
Article code: 1415a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian